Clinical trials involving canakinumab, a monoclonal antibody against IL-1β, has shown a significant reduction of major cardiovascular incidents in patients with atherosclerosis, by reducing the total levels of plasma IL-6 and CRP compared to those given a placebo [83]. Here, IL6 is linked to atherosclerosis.